Growth Research Publishes PROTIA Company Visit Report, Highlighting Its Unrivaled Competitiveness in Allergy Diagnostics

=========================================================

Growth Research, an independent research firm specializing in small-cap companies and led by CEO Han Yong-hee, announced that it has published a company visit report on PROTIA (303360) based on a site visit conducted on the 20th.

The report provides a comprehensive analysis of PROTIA’s competitiveness in the in vitro diagnostics market, its financial performance, and its future growth potential.

Growth Research publishes company visit reports on a weekly basis. Its analysts visit companies in person and conduct question-and-answer sessions with company representatives to provide in-depth analysis based on first-hand information.

Founded in 2000 and listed on the KOSDAQ market in 2023, PROTIA specializes in the manufacture of in vitro diagnostic medical devices. Its main businesses include the production of diagnostic kits and instruments for multiplex allergen testing, or MAST, which accounts for 79.54% of its revenue, as well as the sale of diagnostic instruments and related accessories.

Leveraging its technological capabilities, which the report describes as superior to those of global competitors, PROTIA has developed multiplex allergen testing kits that can be expanded to accommodate up to 400 test lines. This enables efficient and cost-effective allergy testing within the health insurance system.

According to the Growth Research report, PROTIA’s key competitive strengths include its multiplex allergen detection technology, the ability to test for one of the broadest ranges of allergens worldwide, and its in-house technology for producing high-quality allergens at a low cost.

In particular, PROTIA can simultaneously test a large number of allergens using a smaller sample volume than competing products. This technological advantage supports a high-margin business structure.

The company also generates a lock-in effect through the sale of its in vitro diagnostic instruments. Because customers face significant barriers when switching to alternative platforms after adopting the instruments, PROTIA is expected to secure stable, long-term profitability from recurring diagnostic kit sales.

PROTIA recorded revenue of KRW 10.5 billion and operating profit of KRW 1.5 billion last year. In 2025, operating profit is expected to increase as sales of allergy diagnostic kits and diagnostic instruments continue to grow.

In particular, growth in diagnostic instrument sales is expected to serve as a leading indicator for future sales of allergy diagnostic kits.

“PROTIA possesses unrivaled competitiveness in the allergy diagnostics market and is achieving strong operating leverage alongside its rapid expansion in global markets,” said Han Yong-hee, CEO of Growth Research.

The full PROTIA company visit report is available on the official Growth Research website.

source : https://www.ggilbo.com